Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 1 天前评分90
正文 · 机器翻译
FourLight-1 #ESMO26
在经CDK4/6i治疗后进展的HR+/HER2−晚期#BreastCancer中，atirmociclib + fulvestrant将中位无进展生存期（PFS）从6.6个月提升至9.4个月（HR 0.60; p=0.0007）
结果令人鼓舞，但仍需进行3期验证，以确定其在临床实践中的作用。
@OncoAlert
276 浏览 · 14 赞 · 8 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Aya Mohamed | MSc, MD 🎗 · x.com